Literature DB >> 10909961

Fatty acid oxidation and the regulation of malonyl-CoA in human muscle.

P N Båvenholm1, J Pigon, A K Saha, N B Ruderman, S Efendic.   

Abstract

Questions concerning whether malonyl-CoA is regulated in human muscle and whether malonyl-CoA modulates fatty acid oxidation are still unanswered. To address these questions, whole-body fatty acid oxidation and the concentration of malonyl-CoA, citrate, and malate were determined in the vastus lateralis muscle of 16 healthy nonobese Swedish men during a sequential euglycemic-hyperinsulinemic clamp. Insulin was infused at rates of 0.25 and 1.0 mU x kg(-1) x min(-1), and glucose was infused at rates of 2.0 +/- 0.2 and 8.1 +/- 0.7 mg x kg(-1) x min(-1), respectively. During the low-dose insulin infusion, whole-body fatty acid oxidation, as determined by indirect calorimetry, decreased by 22% from a basal rate of 0.94 +/- 0.06 to 0.74 +/- 0.07 mg x kg(-1) x min(-1) (P = 0.005), but no increase in malonyl-CoA was observed. In contrast, during the high-dose insulin infusion, malonyl-CoA increased from 0.20 +/- 0.01 to 0.24 +/- 0.01 nmol/g (P < 0.001), and whole-body fatty acid oxidation decreased by an additional 41% to 0.44 +/- 0.06 mg x kg(-1) x min(-1) (P < 0.001). The increase in malonyl-CoA was associated with 30-50% increases in the concentrations of citrate (102 +/- 6 vs. 137 +/- 7 nmol/g, P < 0.001), an allosteric activator of the rate-limiting enzyme in the malonyl-CoA formation, acetyl-CoA carboxylase, and malate (80 +/- 6 vs. 126 +/- 9 nmol/g, P = 0.002), an antiporter for citrate efflux from the mitochondria. Significant correlations were observed between the concentration of malonyl-CoA and both glucose utilization (r = 0.53, P = 0.002) and the sum of the concentrations of citrate and malate (r = 0.52, P < 0.001), a proposed index of the cytosolic concentration of citrate. In addition, an inverse correlation between malonyl-CoA concentration and fatty acid oxidation was observed (r = -0.32, P = 0.03). The results indicate that an infusion of insulin and glucose at a high rate leads to increases in the concentration of malonyl-CoA in skeletal muscle and to decreases in whole-body and, presumably, muscle fatty acid oxidation. Furthermore, they suggest that the increase in malonyl-CoA in this situation is due, at least in part, to an increase in the cytosolic concentration of citrate. Because cytosolic citrate is also an inhibitor of phosphofructokinase, an attractive hypothesis is that changes in its concentration are part of an autoregulatory mechanism by which glucose modulates its own use and the use of fatty acids as fuels for skeletal muscle.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10909961     DOI: 10.2337/diabetes.49.7.1078

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  13 in total

1.  Malonyl coenzyme A and the regulation of functional carnitine palmitoyltransferase-1 activity and fat oxidation in human skeletal muscle.

Authors:  Blake B Rasmussen; Ulf C Holmbäck; Elena Volpi; Beatrice Morio-Liondore; Douglas Paddon-Jones; Robert R Wolfe
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

Review 2.  Regulation and limitations to fatty acid oxidation during exercise.

Authors:  Jacob Jeppesen; Bente Kiens
Journal:  J Physiol       Date:  2012-01-23       Impact factor: 5.182

3.  Computational model of cellular metabolic dynamics: effect of insulin on glucose disposal in human skeletal muscle.

Authors:  Yanjun Li; Thomas P J Solomon; Jacob M Haus; Gerald M Saidel; Marco E Cabrera; John P Kirwan
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-03-23       Impact factor: 4.310

Review 4.  New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle.

Authors:  Francis B Stephens; Dumitru Constantin-Teodosiu; Paul L Greenhaff
Journal:  J Physiol       Date:  2007-03-01       Impact factor: 5.182

5.  Dynamic changes in fat oxidation in human primary myocytes mirror metabolic characteristics of the donor.

Authors:  Barbara Ukropcova; Michele McNeil; Olga Sereda; Lilian de Jonge; Hui Xie; George A Bray; Steven R Smith
Journal:  J Clin Invest       Date:  2005-07       Impact factor: 14.808

6.  Dysregulation of muscle fatty acid metabolism in type 2 diabetes is independent of malonyl-CoA.

Authors:  J A Bell; E Volpi; S Fujita; J G Cadenas; B B Rasmussen
Journal:  Diabetologia       Date:  2006-07-26       Impact factor: 10.122

Review 7.  [Future targets in the treatment of type 2 diabetes].

Authors:  Harald Stingl; Michael Roden
Journal:  Wien Klin Wochenschr       Date:  2004-04-30       Impact factor: 1.704

8.  Expression of key genes of fatty acid oxidation, including adiponectin receptors, in skeletal muscle of Type 2 diabetic patients.

Authors:  C Debard; M Laville; V Berbe; E Loizon; C Guillet; B Morio-Liondore; Y Boirie; H Vidal
Journal:  Diabetologia       Date:  2004-05-01       Impact factor: 10.122

Review 9.  Malonyl-CoA and AMP-activated protein kinase: an expanding partnership.

Authors:  Asish K Saha; Neil B Ruderman
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

10.  Adenosine Monophosphate-Activated Protein Kinase (AMPK) as a New Target for Antidiabetic Drugs: A Review on Metabolic, Pharmacological and Chemical Considerations.

Authors:  Arie Gruzman; Gali Babai; Shlomo Sasson
Journal:  Rev Diabet Stud       Date:  2009-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.